Opinion|Videos|June 5, 2024
Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease
Experts on Alzheimer disease discuss how the introduction of disease-modifying therapies has impacted the treatment landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What has been the clinical impact and the target patients for the use of anti-amyloid β monoclonal antibodies?
- Aducanumab approved by the FDA in 2021; development and commercialization discontinued on Jan 31, 2024
- Lecanemab approved by the FDA in 2023
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Vutrisiran Effects Consistent With, Without Tafamidis in ATTR-CM
2
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
3
Multiagonists Outpace Older GLP-1 Drugs for Weight Loss
4
Cardiac Risks of COVID-19 Vaccine vs Infection: Eman Toraih, MD, PhD
5